Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study

Diabetes, Obesity and Metabolism

Volumn 18, Issue 8, 2016, Pages 755-765

  Patorno, E ^a   Everett, B M ^a   Goldfine, A B ^b   Glynn, R J ^a   Liu, J ^a   Gopalakrishnan, C ^a   Kim, S C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cardiovascular disease; DPP 4 inhibitor; GLP 1 analogue; insulin therapy; pharmaco epidemiology; sulphonylureas

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPENSITY SCORE; UNITED STATES; UNSTABLE ANGINA PECTORIS; AGONISTS; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; HEART MUSCLE REVASCULARIZATION; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; STROKE;

ADULT; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STROKE; SULFONYLUREA COMPOUNDS;

EID: 84978886151     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12665     Document Type: Article

References (39)

1. International Diabetes Federation. IDF Diabetes Atlas. 6th edn. 2013. Available from URL: http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed 15 December 2015.
2. International Diabetes Federation. IDF Diabetes Atlas. 6th edn. 2014 Update. Available from URL: http://www.idf.org/sites/default/files/Atlas-poster-2014_EN.pdf. Accessed 15 December 2015.
3. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 2013; 127: e6–e245.
4. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421.
5. Sarwar N, Gao P, Seshasai SR et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215–2222.
6. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169.
7. Fisher M. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective. Diabetes Obes Metab 2015; 17: 335–342.
8. Sivertsen J, Rosenmeier J, Holst JJ, Vilsbøll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012; 9: 209–222.
9. Smilowitz NR, Donnino R, Schwartzbard A. Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease. Circulation 2014; 129: 2305–2312.
10. Katout M, Zhu H, Rutsky J et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens 2014; 27: 130–139.
11. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013; 3: pii: e001986.
12. Monami M, Cremasco F, Lamanna C et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011; 2011: 215764.
13. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16: 38–47.
14. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011; 10: 22.
15. Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247–2257.
16. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232–242.
17. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317–1326.
18. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–1335.
19. Best JH, Hoogwerf BJ, Herman WH et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011; 34: 90–95.
20. Mogensen UM, Andersson C, Fosbøl EL et al. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus–a retrospective nationwide study. Diabetes Obes Metab 2014; 16: 1001–1008.
21. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004; 148: 99–104.
22. Wahl PM, Rodgers K, Schneeweiss S et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf 2010; 19: 596–603.
23. Tirschwell DL, Longstreth WT Jr. Validating administrative data in stroke research. Stroke 2002; 33: 2465–2470.
24. Saczynski JS, Andrade SE, Harrold LR et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf 2012; 21(Suppl. 1): 129–140.
25. Rubin D. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757–763.
26. Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf 2012; 21(Suppl. 2): 69–80.
27. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28: 3083–3107.
28. Schneeweiss S, Rassen J, Glynn RJ, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512–522.
29. Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol 2011; 173: 1404–1413.
30. Kleinbaum D, Klein M. Evaluating the proportional hazards assumption. In: Gail M, Krickberg K, Samet J, Tsiatis A, Wong W, eds. Survival Analysis: A Self-Learning Text. 3rd edn. New York: Springer, 2012; 161–200.
31. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993; 46: 1075–1079; discussion 81–90.
32. Medscape Medical News. Top-line data show CV benefit for liraglutide in type 2 diabetes. 2016. Available from URL: http://www.medscape.com/viewarticle/859905. Accessed 16 March 2016.
33. Medscape Medical News. Liraglutide no match for heart failure in early round of FIGHT. 2015. Available from URL: http://www.medscape.com/viewarticle/854229. Accessed 16 March 2016.
34. Nathan DM, Buse JB, Kahn SE et al. GRADE Study Research Group. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 2013; 36: 2254–2261.
35. Paul SK, Klein K, Maggs D, Best JH. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol 2015; 14: 10.
36. Patorno E, Patrick AR, Garry EM et al. Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. Diabetologia 2014; 57: 2237–2250.
37. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149.
38. Costanzo P, Cleland JG, Pellicori P et al. The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study. Ann Intern Med 2015; 162: 610–618.
39. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15: 291–303.